Teva Pharmaceutical Industries annual working capital
2008
2009
2010
2011
2012
2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Working Capital Growth & History (TEVA)
Teva Pharmaceutical Industries's working capital was $490.0M for fiscal 2025.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $490.0M | $734.0M | — |
| 2024 | 2024-12-31 | −$244.0M | −$482.0M | — |
| 2023 | 2023-12-31 | $238.0M | −$344.0M | −59.11% |
| 2022 | 2022-12-31 | $582.0M | −$964.0M | −62.35% |
| 2021 | 2021-12-31 | $1.55B | $1.71B | — |
| 2020 | 2020-12-31 | −$159.0M | $51.0M | — |
| 2019 | 2019-12-31 | −$210.0M | $318.0M | — |
| 2018 | 2018-12-31 | −$528.0M | $2.01B | — |
| 2017 | 2017-12-31 | −$2.54B | −$1.28B | — |
| 2016 | 2016-12-31 | −$1.26B | — | — |
| 2013 | 2013-12-31 | $1.75B | −$1.71B | −49.38% |
| 2012 | 2012-12-31 | $3.47B | $2.69B | +346.20% |
| 2011 | 2011-12-31 | $777.0M | −$1.57B | −66.91% |
| 2010 | 2010-12-31 | $2.35B | −$2.19B | −48.27% |
| 2009 | 2009-12-31 | $4.54B | $1.59B | +54.13% |
| 2008 | 2008-12-31 | $2.94B | — | — |
Teva Pharmaceutical Industries quarterly working capital
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
As of Dec 31, 2014
As of Mar 31, 2015
As of Jun 30, 2015
As of Sep 30, 2015
As of Dec 31, 2015
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$1.89B | −$2.65B | — |
| Q1 2026 | 2026-03-31 | $178.0M | −$193.0M | −52.02% |
| Q4 2025 | 2025-12-31 | $490.0M | $734.0M | — |
| Q3 2025 | 2025-09-30 | $1.25B | $2.73B | — |
| Q2 2025 | 2025-06-30 | $759.0M | $2.16B | — |
| Q1 2025 | 2025-03-31 | $371.0M | $1.87B | — |
| Q4 2024 | 2024-12-31 | −$244.0M | −$482.0M | — |
| Q3 2024 | 2024-09-30 | −$1.48B | −$1.51B | — |
| Q2 2024 | 2024-06-30 | −$1.41B | −$1.65B | — |
| Q1 2024 | 2024-03-31 | −$1.50B | −$2.58B | — |
| Q4 2023 | 2023-12-31 | $238.0M | −$344.0M | −59.11% |
| Q3 2023 | 2023-09-30 | $31.0M | $112.0M | — |
| Q2 2023 | 2023-06-30 | $245.0M | −$923.0M | −79.02% |
| Q1 2023 | 2023-03-31 | $1.09B | $252.0M | +30.07% |
| Q4 2022 | 2022-12-31 | $582.0M | −$964.0M | −62.35% |
| Q3 2022 | 2022-09-30 | −$81.0M | −$410.0M | — |
| Q2 2022 | 2022-06-30 | $1.17B | $1.04B | +791.60% |
| Q1 2022 | 2022-03-31 | $838.0M | $526.0M | +168.59% |
| Q4 2021 | 2021-12-31 | $1.55B | $1.71B | — |
| Q3 2021 | 2021-09-30 | $329.0M | $272.0M | +477.19% |
| Q2 2021 | 2021-06-30 | $131.0M | −$899.0M | −87.28% |
| Q1 2021 | 2021-03-31 | $312.0M | −$250.0M | −44.48% |
| Q4 2020 | 2020-12-31 | −$159.0M | $51.0M | — |
| Q3 2020 | 2020-09-30 | $57.0M | $1.62B | — |
| Q2 2020 | 2020-06-30 | $1.03B | $1.68B | — |
| Q1 2020 | 2020-03-31 | $562.0M | $1.16B | — |
| Q4 2019 | 2019-12-31 | −$210.0M | $318.0M | — |
| Q3 2019 | 2019-09-30 | −$1.56B | −$616.0M | — |
| Q2 2019 | 2019-06-30 | −$647.0M | −$1.14B | — |
| Q1 2019 | 2019-03-31 | −$597.0M | −$528.0M | — |
| Q4 2018 | 2018-12-31 | −$528.0M | $2.01B | — |
| Q3 2018 | 2018-09-30 | −$949.0M | −$232.0M | — |
| Q2 2018 | 2018-06-30 | $496.0M | $1.36B | — |
| Q1 2018 | 2018-03-31 | −$69.0M | $999.0M | — |
| Q4 2017 | 2017-12-31 | −$2.54B | −$1.28B | — |
| Q3 2017 | 2017-09-30 | −$717.0M | $1.18B | — |
| Q2 2017 | 2017-06-30 | −$862.0M | −$4.79B | — |
| Q1 2017 | 2017-03-31 | −$1.07B | −$5.16B | — |
| Q4 2016 | 2016-12-31 | −$1.26B | −$6.65B | — |
| Q3 2016 | 2016-09-30 | −$1.90B | −$1.42B | — |
| Q2 2016 | 2016-06-30 | $3.93B | $5.11B | — |
| Q1 2016 | 2016-03-31 | $4.09B | $845.0M | +26.05% |
| As of Dec 31, 2015 | 2015-12-31 | $5.39B | $3.29B | +155.96% |
| As of Sep 30, 2015 | 2015-09-30 | −$478.0M | −$2.73B | — |
| As of Jun 30, 2015 | 2015-06-30 | −$1.17B | −$2.87B | — |
| As of Mar 31, 2015 | 2015-03-31 | $3.24B | $1.20B | +58.55% |
| As of Dec 31, 2014 | 2014-12-31 | $2.11B | $352.0M | +20.06% |
| Q3 2014 | 2014-09-30 | $2.25B | $507.0M | +29.04% |
| Q2 2014 | 2014-06-30 | $1.69B | $436.0M | +34.71% |
| Q1 2014 | 2014-03-31 | $2.05B | −$14.0M | −0.68% |
| Q4 2013 | 2013-12-31 | $1.75B | −$1.71B | −49.38% |
| Q3 2013 | 2013-09-30 | $1.75B | −$2.61B | −59.94% |
| Q2 2013 | 2013-06-30 | $1.26B | −$2.96B | −70.24% |
| Q1 2013 | 2013-03-31 | $2.06B | $720.0M | +53.73% |
| Q4 2012 | 2012-12-31 | $3.47B | $2.69B | +346.20% |
| Q3 2012 | 2012-09-30 | $4.36B | $2.82B | +183.36% |
| Q2 2012 | 2012-06-30 | $4.22B | $1.67B | +65.36% |
| Q1 2012 | 2012-03-31 | $1.34B | −$1.83B | −57.69% |
| Q4 2011 | 2011-12-31 | $777.0M | −$1.57B | −66.91% |
| Q3 2011 | 2011-09-30 | $1.54B | −$998.0M | −39.35% |
| Q2 2011 | 2011-06-30 | $2.55B | −$3.71B | −59.24% |
| Q1 2011 | 2011-03-31 | $3.17B | −$1.10B | −25.80% |
| Q4 2010 | 2010-12-31 | $2.35B | −$2.19B | −48.27% |
| Q3 2010 | 2010-09-30 | $2.54B | −$1.69B | −39.98% |
| Q2 2010 | 2010-06-30 | $6.26B | $2.47B | +64.98% |
| Q1 2010 | 2010-03-31 | $4.27B | $1.70B | +66.07% |
| Q4 2009 | 2009-12-31 | $4.54B | $1.59B | +54.13% |
| Q3 2009 | 2009-09-30 | $4.22B | — | — |
| Q2 2009 | 2009-06-30 | $3.79B | — | — |
| Q1 2009 | 2009-03-31 | $2.57B | — | — |
| Q4 2008 | 2008-12-31 | $2.94B | — | — |
Teva Pharmaceutical Industries working capital trends
Over the last five fiscal years, Teva Pharmaceutical Industries's working capital increased from −$159.0M to $490.0M, a change of $649.0M. The latest reported quarter, Q2 2026, shows −$1.89B.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teva Pharmaceutical Industries source filings ↗